Zacks Research Brokers Boost Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, May 1st. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.08 per share for the quarter, up from their prior estimate of $0.06. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.12). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

IRWD has been the subject of several other reports. Wells Fargo & Company reissued an "equal weight" rating and issued a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. StockNews.com lowered Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 15th. Leerink Partners reduced their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research report on Monday, April 14th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Trading Down 17.8 %

IRWD traded down $0.16 on Friday, reaching $0.76. The stock had a trading volume of 1,177,993 shares, compared to its average volume of 2,550,764. The company has a market cap of $123.30 million, a P/E ratio of -25.37 and a beta of 0.37. Ironwood Pharmaceuticals has a 12-month low of $0.59 and a 12-month high of $8.23. The business's 50-day moving average price is $1.20 and its two-hundred day moving average price is $2.73.

Insiders Place Their Bets

In related news, CEO Thomas A. Mccourt sold 139,064 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company's stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company's stock, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 192,381 shares of company stock worth $338,591 over the last ninety days. Corporate insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. boosted its holdings in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after acquiring an additional 450,949 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company's stock worth $8,786,000 after buying an additional 78,969 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter worth approximately $53,000. Amundi boosted its position in shares of Ironwood Pharmaceuticals by 168.4% in the fourth quarter. Amundi now owns 61,979 shares of the biotechnology company's stock worth $284,000 after purchasing an additional 38,889 shares during the period. Finally, Los Angeles Capital Management LLC raised its position in shares of Ironwood Pharmaceuticals by 2,625.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company's stock valued at $1,469,000 after buying an additional 319,528 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.